hTERT Epigenetics Provides New Perspectives for Diagnosis and Evidence-Based Guidance of Chemotherapy in Cancer
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25137331 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Simeon Santourlidis und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Transplantation Diagnostics and Cell Therapeutics, Medical Faculty, Heinrich Heine University Duesseldorf, Moorenstr. 5, 40225 Duesseldo…. Hauptthemen laut MEDLINE: Biomarkers, Tumor, DNA Methylation, Epigenesis, Genetic, Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Heinrich-Heine-Universität Düsseldorf.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Strong epigenetic pan-cancer biomarkers are required to meet several current, urgent clinical needs and to further improve the present chemotherapeutic standard. We have concentrated on the investigation of epigenetic alteration of the hTERT gene, which is frequently epigenetically dysregulated in a number of cancers in specific developmental stages. Distinct DNA methylation profiles were identified in our data on early urothelial cancer. An efficient EpihTERT assay could be developed utilizing suitable combinations with sequence-dependent thermodynamic parameters to distinguish between differentially methylated states. We infer from this data set, the epigenetic context, and the related literature that a CpG-rich, 2800 bp region, a prominent CpG island, surrounding the transcription start of the hTERT gene is the crucial epigenetic zone for the development of a potent biomarker. In order to accurately describe this region, we have named it “Acheron” (Ἀχέρων). In Greek mythology, this is the river of woe and misery and the path to the underworld. Exploitation of the DNA methylation profiles focused on this region, e.g., idiolocal normalized Methylation Specific PCR (IDLN-MSP), opens up a wide range of new possibilities for diagnosis, determination of prognosis, follow-up, and detection of residual disease. It may also have broad implications for the choice of chemotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Transplantation Diagnostics and Cell Therapeutics, Medical Faculty, Heinrich Heine University Duesseldorf, Moorenstr. 5, 40225 Duesseldorf, Germany.
- Group of Computational Biology and Systems Biomedicine, Biodonostia Health Research Institute, 20014 San Sebastián, Spain.
- Ikerbasque, Basque Foundation for Science, 48013 Bilbao, Spain.
- Department of Cell Biology and Histology, Faculty of Medicine and Nursing, University of Basque Country (UPV/EHU), 48940 Leioa, Spain.
- Department of Pathology, University of Mississippi Medical Center, Jackson, MS 39216, USA.
- Institut National de la Santé et de la Recherche Médicale, 67000 Strasbourg, France.
ORCID-Profile: Simeon Santourlidis, Marcos J Araúzo-Bravo, Mohamed Hassan
Förderung
- Heinrich-Heine-Universität Düsseldorf
Zitieren
APA
Santourlidis, S., Araúzo-Bravo, M. J., Brodell, R. T., Hassan, M., & Bendhack, M. L. (2024). hTERT Epigenetics Provides New Perspectives for Diagnosis and Evidence-Based Guidance of Chemotherapy in Cancer. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25137331
Vancouver
Santourlidis S, Araúzo-Bravo MJ, Brodell RT, Hassan M, Bendhack ML. hTERT Epigenetics Provides New Perspectives for Diagnosis and Evidence-Based Guidance of Chemotherapy in Cancer. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25137331
BibTeX
@article{Santourlidis2024,
author = {Santourlidis, Simeon and Araúzo-Bravo, Marcos J and Brodell, Robert T and Hassan, Mohamed and Bendhack, Marcelo L},
title = {hTERT Epigenetics Provides New Perspectives for Diagnosis and Evidence-Based Guidance of Chemotherapy in Cancer},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25137331}
}
EUVIMED